Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)

Market Cap	4.78B -12.7%
Revenue (ttm)	459.02M +8.7%
Net Income	33.80M -47.6%
EPS	0.08 -45.3%
Shares Out	417.60M
PE Ratio	143.13
Forward PE	n/a
Dividend	0.06 (0.52%)
Ex-Dividend Date	May 26, 2025

Volume	2,891,191
Average Volume	4,296,537
Open	11.40
Previous Close	11.43
Day's Range	11.28 - 11.56
52-Week Range	10.76 - 16.95
Beta	0.75
RSI	38.88
Earnings Date	Mar 31, 2026

About SHE:301211

Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. The company also provides raw material products, including non-steroidal anti-inflammatory raw materials ibuprofen and dexibuprofen, cardiovascular raw materials torsemide and milrinone, anti-tumor raw material...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 952
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301211

Financial Performance

In 2025, SHE:301211's revenue was 453.31 million, an increase of 1.67% compared to the previous year's 445.86 million. Earnings were 34.91 million, a decrease of -61.87%.